Mr. Rindell has held numerous senior executive roles in the management of life science companies, including VP of Corporate Development & Strategic Planning for Advanced Tissue Sciences, VP of for Global Business Management for Braun/Thermoscan, a division of the Gillette Company, Executive Director of Business Development at Amylin Pharmaceuticals. Mr. Rindell is currently leading Global Device Business Development for Bristol Myers Squibb and is also the Managing Director of Camino International, LLC, a life science consultancy.
As an entrepreneur, he has been responsible for more than 35 years of business growth. As founder and president of The MBA Group of Companies, he has nurtured start-ups and small enterprises by providing strategic vision, marketing innovation, operational expertise and financial acumen that have enabled these businesses to become leaders in their diverse fields.
As a race car driver, he has been a major player on the competitive racing scene for four decades, and continues to be a force on the track.
Eddie Rodriguez is a partner at Teal Ventures, an early stage venture capital fund focused on disruptive innovation in digital/ mobile health and medical devices. Prior to joining Teal Ventures, Eddie was a partner at several national law firms and a recognized corporate attorney in the venture capital and M&A fields. Eddie has represented countless startup and emerging growth companies throughout their life cycles and numerous private and public companies in M&A transactions, in industries including healthcare, medical devices, technology, fin-tech, e-commerce and telecommunications. Eddie has also co-founded several companies in the medical device and technology areas. He has also been an active investor in early stage companies in various industries.
Eddie received his JD from Stanford Law School, where he was the Editor-In-Chief of the Stanford Journal of International Law and the Articles Editor of the Stanford Law and Policy Review. He holds a B.A. from the University of California, Los Angeles.
Dr. Naughton founded Histogen, Inc. in 2007, and currently serves as Chief Scientific Officer and Chief Business Development Officer for the Company. She has spent more than 30 years extensively researching the tissue engineering process, holds more than 100 U.S. and foreign patents and has been extensively published in the field.
She previously served as co-founder and co-inventor of Advanced Tissue Sciences, a manufacturer of human skin for wound healing and skin treatments. At ATS Dr. Naughton held a variety of key management positions, including president, chief operating officer, chief scientific officer and principal scientist. While serving as an officer and director of the Company, Dr. Naughton oversaw the design and development of the world’s first up-scaled manufacturing facility for tissue engineered products, established corporate development and marketing partnerships with companies including Smith & Nephew, Ltd., Medtronic and Inamed Corporation, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four human cell-based products from concept through FDA approval and market launch
Dr. Willms is a practicing Pulmonary Disease Specialist in San Diego, CA. Dr. Willms graduated from Baylor College of Medicine in 1982 and has been in practice for 37 years.
He completed a residency at University Hospital South Texas Medical Center. Dr. Willms also specializes in Critical Care Medicine and Internal Medicine. He currently practices at Charles Frederick Landers MD and is affiliated with Sharp Memorial Hospital. Dr. Willms accepts multiple insurance plans including Medicare, Cigna, and Medicaid.
Dr. Willms is board certified in Internal Medicine. Dr. Willms also practices at Sharp Memorial Hospital in San Diego, CA.